![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Celadon Pharmaceuticals Plc | LSE:CEL | London | Ordinary Share | GB00BDQYGP38 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 75.00 | 73.00 | 77.00 | 75.00 | 75.00 | 75.00 | 15,135 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Investment Advice | 149k | -7.14M | -0.1082 | -6.93 | 49.49M |
RNS Number:8476L Celsis International PLC 16 January 2008 Celsis International plc ("the Company") Non-Executive Director Shareholding 16 January 2008: The Company was notified on 15 January 2008 that on 14 January 2008 Mr Nicholas Badman, Non-Executive Director of the Company, purchased 2,230 ordinary shares of 5 pence each in the Company at a price of 178.5 pence per ordinary share. Following this purchase Mr Badman's beneficial interest in the Company is 2,230 ordinary shares, representing a total of 0.01% of the issued share capital of the Company. Enquiries: Celsis International plc Tel: 01223 598 428 Christian Madrolle, Finance Director and Company Secretary Jenny Woolway, Corporate Communications Financial Dynamics Tel: 020 7831 3113 David Yates Ben Atwell This information is provided by RNS The company news service from the London Stock Exchange END RDSBRGDBRGBGGIU
1 Year Celadon Pharmaceuticals Chart |
1 Month Celadon Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions